Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced imaging, nanotech tools in NIH institute’s long-term plan

This article was originally published in The Gray Sheet

Executive Summary

Disease prevention, diagnosis and treatment will require major investments in technology development, the National Heart, Lung and Blood Institute says. A new strategic plan calls for public/private collaboration and will help guide NHLBI research priorities for the next 5-10 years. Goals include pinpointing genetic variants and biomarkers linked to specific diseases, developing in vivo molecular imaging methods and probes to study the biology of disease processes, and developing DNA sequencing technology that detects even rare gene variants. The institute aims to help develop new tools in areas ranging from genomics, imaging and nanotechnology to tissue engineering. Nanotechnology, for one, could be used to diagnose and treat vulnerable plaque, to make devices that monitor for the onset of thrombotic or hemorrhagic events, and to create in vivo sensors to monitor patients for sleep apnea. NHLBI also will explore noninvasive imaging techniques for early risk stratification and diagnosis of cardiovascular, lung and blood disorders

You may also be interested in...



Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Dr Reddy’s And Hikma Win Big On US Vascepa Patents

In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.

Manipulating Metabolism: Lilly Links With UK Biotech Sitryx

Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.

UsernamePublicRestriction

Register

MT025562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel